Denis Katz, MD
Alzheimer’s disease (AD) drug development remains the most capital-intensive and failure-prone domain in biopharma. The so-called “Alzheimer’s graveyard” reflects decades of scientific promise undermined by regulatory, operational, and strategic misalignment.
https://salienceclinical.com/
Denis Katz, MD Alzheimer’s disease (AD) drug development remains the most capital-intensive and failure-prone domain in biopharma. The so-called “Alzheimer’s graveyard” reflects decades of scientific promise undermined by regulatory, operational, and strategic misalignment. https://salienceclinical.com/
0 Комментарии 0 Поделились 0 Отзывы
Реклама
VintFint https://vintfint.com